D. Han; D.S. Mytelka; G.L. Warren; M. Ciarametaro; M. Trusheim. PharmaExec.com, 2018
After decades of anticipation, 2017 saw the approval of the first of a new generation of durable and potentially curative gene and cell therapies. Over the next five years, it has been estimated that about 40 new gene and cell therapies will launch1 [1], with more to come from a global pipeline of 1,148 products in clinical development spanning a wide range of diseases.2 While these products have the potential to improve the lives of patients dramatically, they will also create substantial challenges for the healthcare system, including concerns about affordability and the need for novel financing approaches to manage the disconnect between short-term treatments and extended/uncertain periods of benefit.